Lipid Metabolic Status in Thyroid Carcinoma
Raktažodžiai
Santrauka
apibūdinimas
Although considered a rare type of cancer with an incidence under 6 cases for 100 000 persons, the thyroid carcinoma is the most frequent endocrine tumor. The incidence of this malignant disease has exponentially increased in the last decade, so that many specially centers in the world have focused on a better strategy of diagnosis, of treatment and of monitoring. By applying a suitable multimodal treatment, the prognosis of this disease is excellent, offering the patients a survival rate of over 90% at 10 years. During the monitoring of the disease, the patients are periodically supposed to withdraw the hormone treatment; because of this hormone imbalance, there will be important changes of the metabolism, especially the lipid one. This is the reason why we are preoccupied to increase the quality of life of the patients addicted to a chronic thyroid hormone therapy. The aim of this study is to demonstrate the way in which the lipid profile is influenced and to quantify the cardiovascular risk for the patients radically treated of thyroid cancer, by total thyroidectomy, metabolic irradiation and undergoing a chronic thyroid hormone treatment. Nowadays, Romania is one of the countries in which these patients are supposed to be kept in a iatrogenous myxoedema, the alternative being the recombinant thyroid stimulating hormone. For the patients with the mentioned diagnosis, the lipid profile will be determined and will consist of the following: total serologic cholesterol, cholesterol fractions, triglycerides and C reactive protein highly sensitive (hsCRP). A score for the cardiovascular accident risk will be elaborated. The attempt of classifying in cardiovascular risk groups the patients through the present study, would facilitate the selection of the patients and their access to therapies and modern monitoring strategies.
Datos
Paskutinį kartą patikrinta: | 11/30/2012 |
Pirmasis pateikimas: | 12/04/2011 |
Numatytas registravimas pateiktas: | 12/05/2011 |
Pirmas paskelbtas: | 12/06/2011 |
Paskutinis atnaujinimas pateiktas: | 12/25/2012 |
Paskutinis atnaujinimas paskelbtas: | 12/26/2012 |
Faktinė studijų pradžios data: | 01/31/2011 |
Numatoma pirminio užbaigimo data: | 01/31/2012 |
Numatoma studijų užbaigimo data: | 04/30/2012 |
Būklė ar liga
Fazė
Rankų grupės
Ranka | Intervencija / gydymas |
---|---|
Thyroid cancer, lipids, LT4 withdrawal | |
Thyroid cancer, Lipids, LT4 substitution |
Tinkamumo kriterijai
Amžius, tinkami studijuoti | 18 Years Į 18 Years |
Tinkamos studijoms lytys | All |
Mėginių ėmimo metodas | Probability Sample |
Priima sveikus savanorius | Taip |
Kriterijai | Inclusion Criteria: - thyroid carcinoma radically treated (surgery, radioiodine, thyroid hormone suppression ) Exclusion Criteria: - other causes of high CRP (infection, inflammation) |
Rezultatas
Pirminės rezultatų priemonės
1. hsCRP an inflammatory biomarker for cardiovascular risk [May 2012]
Antrinės rezultatų priemonės
1. hsCRP may increase in repeated thyroid hormone withdrawal [May 2012]
Kitos rezultato priemonės
1. hsCRP related to thyroid hormone withdrawal in patients with thyroid carcinoma radically treated [May 2012]